获取途径

作者

张芳蕾 周振虎

作者单位

聊城市人民医院核医学科，山东 聊城 山东第一医科大学(山东省医学科学院)研究生部，山东 济南

刊名

Advances in Clinical Medicine

年份

2023

卷号

Vol.13 No.10

页码

15415-15422

ISSN

2161-8712

关键词

安罗替尼 碘难治性分化型甲状腺癌 疗效 不良反应 Anlotinib Iodine-Refractory Differentiated Thyroid Cancer Efficacy Adverse Reactions

摘要

Objective: To evaluate the short-term efficacy and safety of anlotinib in the treatment of iodine- re-fractory differentiated thyroid carcinoma. Methods: The clinical data of 23 patients with iodine- re-fractory differentiated thyroid cancer who received anlotinib targeted therapy for 3 months were collected from June 2021 to June 2023 in Liaocheng People’s Hospital. The efficacy of the target le-sions was evaluated according to the solid tumor efficacy evaluation criteria version 1.1, including...更多

Objective: To evaluate the short-term efficacy and safety of anlotinib in the treatment of iodine- re-fractory differentiated thyroid carcinoma. Methods: The clinical data of 23 patients with iodine- re-fractory differentiated thyroid cancer who received anlotinib targeted therapy for 3 months were collected from June 2021 to June 2023 in Liaocheng People’s Hospital. The efficacy of the target le-sions was evaluated according to the solid tumor efficacy evaluation criteria version 1.1, including objective response rate and disease control rate . The maximum diameter changes of thyroglobulin and target lesions were compared before and after drug withdrawal, and adverse reactions were recorded during medication. Results: A total of 23 patients were enrolled. After 3 months of treatment with anlotinib, 13 patients achieved partial remission , 8 patients were stable, and no patients achieved complete remission, with ORR of 56.52% and DCR of 91.3%. At the last follow-up, Tg levels decreased from 119.14 ng/mL to 27.98 ng/mL . The maximum diameter of the target le-sion decreased from 1.6 cm at baseline to 1.1 cm . The com-mon adverse reactions of anlotinib were hypertension in 6 cases, hand-foot syndrome in 4 cases, and hypertriglyceridemia in 2 cases. No grade 3 or higher adverse reactions associated with anlo-tinib were observed. Two of the patients had good blood pressure control after symptomatic treat-ment with antihypertensive drugs due to persistent hypertension, and the other patients were able to tolerate adverse drug reactions. Conclusion: This study suggests that anlotinib has clear efficacy in the short-term treatment of iodine-refractory differentiated thyroid cancer, with significant tu-mor shrin- kage effect, small adverse reactions, good tolerance and high safety.收起

文献类型

期刊

浏览量

25